These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29763467)

  • 1. Natural disease history of the dy2J mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy.
    Pasteuning-Vuhman S; Putker K; Tanganyika-de Winter CL; Boertje-van der Meulen JW; van Vliet L; Overzier M; Plomp JJ; Aartsma-Rus A; van Putten M
    PLoS One; 2018; 13(5):e0197388. PubMed ID: 29763467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD.
    Moreira Soares Oliveira B; Durbeej M; Holmberg J
    PLoS One; 2017; 12(8):e0181950. PubMed ID: 28771630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased polyamines as protective disease modifiers in congenital muscular dystrophy.
    Kemaladewi DU; Benjamin JS; Hyatt E; Ivakine EA; Cohn RD
    Hum Mol Genet; 2018 Jun; 27(11):1905-1912. PubMed ID: 29566247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib Does Not Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy.
    Körner Z; Durbeej M
    PLoS One; 2016; 11(1):e0146471. PubMed ID: 26731667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F.
    Pasteuning-Vuhman S; Putker K; Tanganyika-de Winter CL; Boertje-van der Meulen JW; van Vliet L; Overzier M; Plomp JJ; Aartsma-Rus A; van Putten M
    PLoS One; 2017; 12(8):e0182704. PubMed ID: 28797108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination.
    Patton BL; Wang B; Tarumi YS; Seburn KL; Burgess RW
    J Cell Sci; 2008 May; 121(Pt 10):1593-604. PubMed ID: 18430779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.
    Doe JA; Wuebbles RD; Allred ET; Rooney JE; Elorza M; Burkin DJ
    J Cell Sci; 2011 Jul; 124(Pt 13):2287-97. PubMed ID: 21652631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy.
    Rooney JE; Knapp JR; Hodges BL; Wuebbles RD; Burkin DJ
    Am J Pathol; 2012 Apr; 180(4):1593-602. PubMed ID: 22322301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic plasticity in the dy2J mouse model of laminin alpha2-deficient congenital muscular dystrophy.
    Anderson JL; Head SI; Morley JW
    Brain Res; 2005 Apr; 1042(1):23-8. PubMed ID: 15823249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin).
    Allamand V; Guicheney P
    Eur J Hum Genet; 2002 Feb; 10(2):91-4. PubMed ID: 11938437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous muscular dystrophy caused by a retrotransposal insertion in the mouse laminin alpha2 chain gene.
    Besse S; Allamand V; Vilquin JT; Li Z; Poirier C; Vignier N; Hori H; Guénet JL; Guicheney P
    Neuromuscul Disord; 2003 Mar; 13(3):216-22. PubMed ID: 12609503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.
    Hara Y; Mizobe Y; Miyatake S; Takizawa H; Nagata T; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1828():553-564. PubMed ID: 30171567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiology of the neuromuscular junction of the laminin-2 (merosin) deficient C57 BL/6J dy2J/dy2J dystrophic mouse.
    Edwards JP; Hatton PA; Wareham AC
    Brain Res; 1998 Mar; 788(1-2):262-8. PubMed ID: 9555049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models.
    Kuang W; Xu H; Vachon PH; Liu L; Loechel F; Wewer UM; Engvall E
    J Clin Invest; 1998 Aug; 102(4):844-52. PubMed ID: 9710454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired fetal muscle development and JAK-STAT activation mark disease onset and progression in a mouse model for merosin-deficient congenital muscular dystrophy.
    Nunes AM; Wuebbles RD; Sarathy A; Fontelonga TM; Deries M; Burkin DJ; Thorsteinsdóttir S
    Hum Mol Genet; 2017 Jun; 26(11):2018-2033. PubMed ID: 28334989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel mutant transcript of laminin alpha 2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice.
    Sunada Y; Bernier SM; Utani A; Yamada Y; Campbell KP
    Hum Mol Genet; 1995 Jun; 4(6):1055-61. PubMed ID: 7655459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study.
    Bouman K; Groothuis JT; Doorduin J; van Alfen N; Udink Ten Cate FEA; van den Heuvel FMA; Nijveldt R; van Tilburg WCM; Buckens SCFM; Dittrich ATM; Draaisma JMT; Janssen MCH; Kamsteeg EJ; van Kleef ESB; Koene S; Smeitink JAM; Küsters B; van Tienen FHJ; Smeets HJM; van Engelen BGM; Erasmus CE; Voermans NC
    BMC Neurol; 2021 Aug; 21(1):313. PubMed ID: 34384384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice.
    Guo LT; Zhang XU; Kuang W; Xu H; Liu LA; Vilquin JT; Miyagoe-Suzuki Y; Takeda S; Ruegg MA; Wewer UM; Engvall E
    Neuromuscul Disord; 2003 Mar; 13(3):207-15. PubMed ID: 12609502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A.
    Yamauchi J; Kumar A; Duarte L; Mehuron T; Girgenrath M
    Hum Mol Genet; 2013 Nov; 22(21):4306-17. PubMed ID: 23773998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.
    Gawlik KI; Holmberg J; Svensson M; Einerborg M; Oliveira BM; Deierborg T; Durbeej M
    Sci Rep; 2017 Mar; 7():44059. PubMed ID: 28281577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.